Treatment of Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
Status:
Completed
Trial end date:
2019-10-21
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the maximum tolerated dose of the combination of
vorinostat, cisplatin, pemetrexed, and radiation therapy in patients with unresectable stage
IIIA/IIIB non-small cell lung cancer.